Clostridium difficile infections : what is new?
C. difficile is the most common infectious cause of healthcare-associated diarrhea but now is increasingly recognized as a cause of diarrhea in outpatients and persons without apparent health care contacts. Emergence and spread of new epidemic clones of C. difficile 027 (PCR-ribotype) and 078/126 (toxinotype) with increase toxin production, an aditional binary toxin and high level resistance to fluoroquinolones and increasing incidence of more rapidly progressive severe disease, require prompt clinical recognition and new tools to predict severity and to prevent recurrences. Although antibiotics are effective at inhibiting C. difficile and treating symptoms, these drugs could not reestablish normal bowel flora and the rate of recurrences is 25%. During the past years we assisted to an impressive search for new and more effective therapy that shoud be save, with low potential for the development of resistance, with low levels of systemic absorbtion and high levels of active drug in the colon and should be associated with a low rate of recurrence after treatment. By consequence, different approaches to the management of recurrent infections have been studied such as new antibiotics (fidaxomicin), human monoclonal antibodies against C. difficile toxins A and B, intravenous human immunoglobulin, active immunization, and probiotic therapy.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:115 |
|---|---|
| Enthalten in: |
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi - 115(2011), 3 vom: 05. Juli, Seite 656-61 |
| Sprache: |
Rumänisch |
|---|
| Weiterer Titel: |
Infectia cu Clostridium difficile: noi provocări |
|---|
| Beteiligte Personen: |
Miftode, Egidia [VerfasserIn] |
|---|
| Themen: |
Aminoglycosides |
|---|
| Anmerkungen: |
Date Completed 12.01.2012 Date Revised 09.12.2020 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM212688669 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM212688669 | ||
| 003 | DE-627 | ||
| 005 | 20231224020029.0 | ||
| 007 | tu | ||
| 008 | 231224s2011 xx ||||| 00| ||rum c | ||
| 028 | 5 | 2 | |a pubmed24n0709.xml |
| 035 | |a (DE-627)NLM212688669 | ||
| 035 | |a (NLM)22046768 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rum | ||
| 100 | 1 | |a Miftode, Egidia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clostridium difficile infections |b what is new? |
| 246 | 3 | 3 | |a Infectia cu Clostridium difficile: noi provocări |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2012 | ||
| 500 | |a Date Revised 09.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a C. difficile is the most common infectious cause of healthcare-associated diarrhea but now is increasingly recognized as a cause of diarrhea in outpatients and persons without apparent health care contacts. Emergence and spread of new epidemic clones of C. difficile 027 (PCR-ribotype) and 078/126 (toxinotype) with increase toxin production, an aditional binary toxin and high level resistance to fluoroquinolones and increasing incidence of more rapidly progressive severe disease, require prompt clinical recognition and new tools to predict severity and to prevent recurrences. Although antibiotics are effective at inhibiting C. difficile and treating symptoms, these drugs could not reestablish normal bowel flora and the rate of recurrences is 25%. During the past years we assisted to an impressive search for new and more effective therapy that shoud be save, with low potential for the development of resistance, with low levels of systemic absorbtion and high levels of active drug in the colon and should be associated with a low rate of recurrence after treatment. By consequence, different approaches to the management of recurrent infections have been studied such as new antibiotics (fidaxomicin), human monoclonal antibodies against C. difficile toxins A and B, intravenous human immunoglobulin, active immunization, and probiotic therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Aminoglycosides |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Fluoroquinolones |2 NLM | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Fidaxomicin |2 NLM | |
| 650 | 7 | |a Z5N076G8YQ |2 NLM | |
| 700 | 1 | |a Leca, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Dorneanu, Olivia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi |d 1961 |g 115(2011), 3 vom: 05. Juli, Seite 656-61 |w (DE-627)NLM000103667 |x 0048-7848 |7 nnns |
| 773 | 1 | 8 | |g volume:115 |g year:2011 |g number:3 |g day:05 |g month:07 |g pages:656-61 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 115 |j 2011 |e 3 |b 05 |c 07 |h 656-61 | ||